跳至主要内容
临床试验/EUCTR2007-003233-16-FR
EUCTR2007-003233-16-FR进行中(未招募)不适用

A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation.

Theratechnologies Inc.0 个研究点目标入组 300 人开始时间: 2007年7月31日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Subjects who have completed the 26 weeks treatment period of the TH9507-CTR-1011 study.
  • 2. Signed informed consent before any trial-related activities.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Fasting blood glucose >8.33 mmol/L (150 mg/dL) at the end of the TH9507-CTR-1011 study.

研究者

相似试验

进行中(未招募)
不适用
A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation.HIV-associated lipodystrophyMedDRA version: 9.1Level: LLTClassification code 10024608Term: Lipodystrophy
EUCTR2007-003233-16-BETheratechnologies Inc.300
尚未招募
3 期
A Study of JT001 (VV116) for the Early Treatment of Mild to Moderate COVID-19
PACTR202210559228718Shanghai JunTop Biosciences Co LTD1,310
进行中(未招募)
不适用
A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat AccumulatioHIV-associated lipodystrophyMedDRA version: 8.1Level: LLTClassification code 10024608Term: Lipodystrophy
EUCTR2006-005444-88-BETheratechnologies Inc.400
进行中(未招募)
1 期
A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat AccumulatioHIV-associated lipodystrophyMedDRA version: 8.1 Level: LLT Classification code 10024608 Term: Lipodystrophy
EUCTR2006-005444-88-GBTheratechnologies Inc.400
进行中(未招募)
不适用
A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulatio
EUCTR2006-005444-88-FRTheratechnologies Inc.400